Standard Biotools Inc.: 5%+ holders

As of November 10, 2026, 5 holders' latest Schedule 13D or 13G filings report owning 5% or more of Standard Biotools Inc. The largest reported stake is Casdin Capital, LLC's, at 23.9%. 9 filings are on record since November 28, 2025 (Schedule 13D/A, June 9, 2026).

Casdin Capital, LLC also filed stake reports on 3 other companies ↓

Sell to companies like Standard Biotools Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Your website Find my buyers

Opens in a new tab. No signup.

Key facts

• Filing 2026-08-14 · Reporting person: Mak Capital One LLC · Sole voting: 0 · Shared voting: 28,813,904 · Sole dispositive: 0 · Shared dispositive: 28,813,904 · SCHEDULE 13G/A, 2026-08-14
• Filing 2026-08-14 · Reporting person: Long Focus Capital Management, LLC · Sole voting: 0 · Shared voting: 23,500,000 · Sole dispositive: 0 · Shared dispositive: 23,500,000 · SCHEDULE 13G, 2026-08-14
• Filing 2026-07-30 · Reporting person: BlackRock, Inc. · Sole voting: 7,911,347 · Shared voting: 0 · Sole dispositive: 7,911,347 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-07-30
• Filing 2026-06-12 · Reporting person: Viking Global Investors LP · Sole voting: 0 · Shared voting: 58,651,170 · Sole dispositive: 0 · Shared dispositive: 58,651,170 · SCHEDULE 13D, 2026-06-12
• Filing 2026-06-09 · Reporting person: Casdin Capital, LLC · Sole voting: 0 · Shared voting: 88,783,856 · Sole dispositive: 0 · Shared dispositive: 88,783,856 · SCHEDULE 13D/A, 2026-06-09

Standard Biotools Inc. has 9 Schedule 13D or 13G filings on record since 2025-11-28. 5 holders' latest filing reports 5% or more of common stock, $0.001 par value per share. Each figure below is the holder's own, as filed, with the filing linked.

Holders

Swipe the table sideways to see every column.

Holding shares or following this stake? See who's behind Standard Biotools Inc. and the warning signs.

See Standard Biotools Inc.'s free Snapshot Watch Standard Biotools Inc.: email me the next time it files something

Free to see. No signup.

Keep reading

More on Standard Biotools Inc. and the records around it.

Standard Biotools Inc. elsewhere on the record

• Who owns it

Companies that share a holder

• Casdin Capital, LLC also filed stake reports on 3 other companies: BIOLIFE SOLUTIONS INC (Jun 2026), Relay Therapeutics, Inc. (Feb 2026), Codexis, Inc. (Nov 2025)
• MAK CAPITAL ONE LLC also filed stake reports on 3 other companies: PERMA FIX ENVIRONMENTAL SERVICES INC (Aug 2026), ClearPoint Neuro, Inc. (Aug 2026), HEIDRICK & STRUGGLES INTERNATIONAL INC (Nov 2025)
• MAK Capital Fund LP also filed stake reports on 7 other companies: Comstock Inc. (Oct 2026), Autolus Therapeutics plc (May 2026), ClearPoint Neuro, Inc. (May 2026)

Want the whole picture on Standard Biotools Inc.?

Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC

A Full Report on Standard Biotools Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Standard Biotools Inc. covers

1. The Short Answer

2. Which Company This Is

3. What They Do, And How The Money Works

4. Who Runs It, And How To Reach Them

5. The Money: Funding, Valuation, Runway

6. Who Pays Them, And Who They Are Up Against

7. Warning Bells

8. Sources

   10 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

Order Full ReportSee a sample report

A real finished report, first screen. Opens in a new tab.

Voting and dispositive power, as filed

Swipe the table sideways to see every column.

The latest filing identifies Standard Biotools Inc. by CUSIP 34385P108 and gives its principal executive office as 50 MILK STREET, 10TH FLOOR, BOSTON, MA 02109 (SCHEDULE 13G/A, 2026-08-14).

What the percentages are based on

7.3% The calculation is based upon 28,813,904 shares of Common Stock beneficially owned as of 06/30/2026 and a total of 392,578,808 shares of Common Stock, $0.001 par value per share, outstanding as of August 3, 2026, as reported by the Issuer on its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 5, 2026.Mak Capital One LLC, SCHEDULE 13G/A, 2026-08-14

Source of funds (Item 3)

On January 23, 2022, the Issuer agreed to issue and sell (a) 78,750 shares of Series B-1 Convertible Preferred Stock ("Series B-1 Preferred Stock") to Casdin PMF in exchange for cash consideration of $78,750,000 and (b) 33,750 shares of Series B-1 Preferred Stock to Casdin PGEII in exchange for cash consideration of $33,750,000. Pursuant to the Loan Agreement (defined below), (i) Casdin PMF provided a term loan to the Issuer in an aggregate original principal amount of $8,750,000 and (ii) Casdin PGEII provided a term loan to the Issuer in an aggregate original principal amount of $3,750,000.Casdin Capital, LLC, SCHEDULE 13D/A, 2026-06-09

The information set forth in Item 3 of the Schedule 13D filed by the Reporting Persons on October 16, 2023 (the "Previous 13D") is incorporated by reference herein.Viking Global Investors LP, SCHEDULE 13D, 2026-06-12

Purpose of Transaction (Item 4)

Casdin Capital, LLC

Item 4 of the Schedule 13D amendment filed on November 28, 2025 is hereby supplemented by the addition of the following: On June 6, 2026, the Issuer, Treeline Biosciences, Inc., a Delaware corporation (the "Company"), and Siri Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Issuer ("Merger Sub"), entered into an Agreement and Plan of Merger and Reorganization (the "Merger Agreement"), pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub will merge with and into the Company, with the Company continuing as a wholly owned subsidiary of the Issuer and the surviving corporation of the merger (the "Merger"). Upon the terms and subject to the conditions set forth in the Merger Agreement, at the effective time of the Merger ("Effective Time"), each share of capital stock of the Company will be converted into the right to receive a number of Shares in accordance with the Exchange Ratio (as defined in the Merger Agreement). Voting Agreement Also on June 6, 2026, in connection with the Merger Agreement, the Issuer, the Company and Merger Sub entered into a voting agreement (the "Voting Agreement") with Casdin Private Growth Equity Fund II, L.P., Casdin Private Growth Equity Fund, L.P., Casdin Partners Master Fund, L.P. and Eli Casdin (collectively, the "Casdin Parties"). Pursuant to the Voting Agreement, the Casdin Parties have agreed, among other things, …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-06-09; the filing has the rest

Viking Global Investors LP

The response to Item 3 of this Schedule 13D is incorporated by reference herein. On June 6, 2026, the Issuer, Treeline Biosciences, Inc., a Delaware corporation ("Treeline"), and Siri Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Issuer ("Merger Sub"), entered into an Agreement and Plan of Merger and Reorganization (the "Merger Agreement"), pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub will merge with and into Treeline, with Treeline continuing as a wholly owned subsidiary of the Issuer and the surviving corporation of the merger (the "Merger"). Upon the terms and subject to the conditions set forth in the Merger Agreement, at the effective time of the Merger ("Effective Time"), each share of capital stock of Treeline will be converted into the right to receive a number of shares of Common Stock in accordance with the Exchange Ratio (as defined in the Merger Agreement). Also on June 6, 2026, in connection with the Merger Agreement, the Issuer, Treeline and Merger Sub entered into a voting agreement (the "Voting Agreement") with VGOP and VGOD. Pursuant to the Voting Agreement, VGOP and VGOD have agreed, among other things, subject to the terms and conditions thereof, to: (i) vote their beneficially owned securities of the Issuer: (1) in favor of the approval of (i) the issuance of Common Stock to holders of Treeline stock pursuant to the Merger …The first part of Item 4 of the SCHEDULE 13D filed 2026-06-12; the filing has the rest

Timeline

Swipe the table sideways to see every column.

Questions about who owns Standard Biotools Inc.

Who owns Standard Biotools Inc.?

On this page, 5 holders' latest ownership filings report 5% or more of Standard Biotools Inc.: Casdin Capital, LLC (23.9%, Schedule 13D/A, filed 2026-06-09), Viking Global Investors LP (15%, Schedule 13D, filed 2026-06-12), Mak Capital One LLC (7.3%, Schedule 13G/A, filed 2026-08-14), MAK Capital Fund LP (6.7%, Schedule 13G/A, filed 2026-05-15) and Long Focus Capital Management, LLC (6%, Schedule 13G, filed 2026-08-14).

Who are the largest shareholders of Standard Biotools Inc.?

By the share each holder's latest filing reports, the largest holders of Standard Biotools Inc. on this page are Casdin Capital, LLC (23.9%), Viking Global Investors LP (15%) and Mak Capital One LLC (7.3%).

When did Casdin Capital, LLC buy into Standard Biotools Inc.?

The filings give report dates, not purchase dates. The earliest filing from Casdin Capital, LLC on this page is the Schedule 13D/A, filed 2025-11-28, reporting 24.2%; its latest, Schedule 13D/A filed 2026-06-09, reports 23.9%. That earliest filing is itself an amendment, which updates an earlier report.

Is this an audit or a full list?

Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 9 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.

Also on the record for Standard Biotools Inc.

Swipe the table sideways to see every column.

Tools for this story

Each opens in a new tab, filled in for Standard Biotools Inc.. With no account yet, you sign up free and land on the result.

• Get an alert when Standard Biotools Inc. is mentioned again
• Find former Standard Biotools Inc. employees to interview
• Verify a claim or statistic

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes